Alx Oncology Holdings Stock EBITDA

ALXO Stock  USD 1.47  0.06  4.26%   
Alx Oncology Holdings fundamentals help investors to digest information that contributes to Alx Oncology's financial success or failures. It also enables traders to predict the movement of Alx Stock. The fundamental analysis module provides a way to measure Alx Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alx Oncology stock.
Last ReportedProjected for Next Year
EBITDA-158.4 M-150.5 M
As of the 26th of November 2024, EBITDA is likely to grow to about (150.5 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Alx Oncology Holdings Company EBITDA Analysis

Alx Oncology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Alx Oncology EBITDA

    
  (158.4 M)  
Most of Alx Oncology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alx Oncology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Alx EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Alx Oncology is extremely important. It helps to project a fair market value of Alx Stock properly, considering its historical fundamentals such as EBITDA. Since Alx Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alx Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alx Oncology's interrelated accounts and indicators.
-0.380.99-0.85-0.650.510.450.940.681.01.0-0.960.990.940.380.960.92-0.32-0.320.42
-0.38-0.310.74-0.19-0.080.01-0.27-0.18-0.39-0.410.22-0.42-0.220.26-0.24-0.21-0.61-0.610.4
0.99-0.31-0.81-0.690.560.520.970.660.990.98-0.970.970.970.410.970.96-0.35-0.350.5
-0.850.74-0.810.18-0.17-0.27-0.7-0.69-0.86-0.880.69-0.9-0.670.09-0.7-0.66-0.19-0.190.07
-0.65-0.19-0.690.18-0.87-0.46-0.8-0.16-0.63-0.590.83-0.54-0.83-0.93-0.83-0.820.810.81-0.93
0.51-0.080.56-0.17-0.870.240.74-0.060.50.44-0.670.390.740.850.710.74-0.49-0.490.83
0.450.010.52-0.27-0.460.240.550.210.460.42-0.560.40.550.390.520.56-0.26-0.260.48
0.94-0.270.97-0.7-0.80.740.550.510.940.91-0.970.881.00.580.991.0-0.41-0.410.66
0.68-0.180.66-0.69-0.16-0.060.210.510.680.71-0.530.730.51-0.090.540.51-0.08-0.080.06
1.0-0.390.99-0.86-0.630.50.460.940.681.0-0.950.990.930.360.950.92-0.31-0.310.41
1.0-0.410.98-0.88-0.590.440.420.910.711.0-0.931.00.910.310.930.89-0.29-0.290.35
-0.960.22-0.970.690.83-0.67-0.56-0.97-0.53-0.95-0.93-0.91-0.98-0.62-0.99-0.970.520.52-0.64
0.99-0.420.97-0.9-0.540.390.40.880.730.991.0-0.910.880.250.910.86-0.26-0.260.29
0.94-0.220.97-0.67-0.830.740.551.00.510.930.91-0.980.880.610.991.0-0.46-0.460.69
0.380.260.410.09-0.930.850.390.58-0.090.360.31-0.620.250.610.60.6-0.8-0.80.92
0.96-0.240.97-0.7-0.830.710.520.990.540.950.93-0.990.910.990.60.98-0.49-0.490.65
0.92-0.210.96-0.66-0.820.740.561.00.510.920.89-0.970.861.00.60.98-0.43-0.430.7
-0.32-0.61-0.35-0.190.81-0.49-0.26-0.41-0.08-0.31-0.290.52-0.26-0.46-0.8-0.49-0.431.0-0.77
-0.32-0.61-0.35-0.190.81-0.49-0.26-0.41-0.08-0.31-0.290.52-0.26-0.46-0.8-0.49-0.431.0-0.77
0.420.40.50.07-0.930.830.480.660.060.410.35-0.640.290.690.920.650.7-0.77-0.77
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

Alx Ebitda

Ebitda

(150.48 Million)

Alx Oncology reported last year EBITDA of (158.4 Million)
According to the company disclosure, Alx Oncology Holdings reported earnings before interest,tax, depreciation and amortization of (158.4 Million). This is 118.05% lower than that of the Biotechnology sector and 258.16% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.06% higher than that of the company.

Alx EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alx Oncology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alx Oncology could also be used in its relative valuation, which is a method of valuing Alx Oncology by comparing valuation metrics of similar companies.
Alx Oncology is currently under evaluation in ebitda category among its peers.

Alx Oncology Institutional Holders

Institutional Holdings refers to the ownership stake in Alx Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alx Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alx Oncology's value.
Shares
Millennium Management Llc2024-06-30
1.3 M
State Street Corp2024-06-30
705.5 K
Geode Capital Management, Llc2024-09-30
700.8 K
Two Sigma Investments Llc2024-09-30
660.1 K
Marshall Wace Asset Management Ltd2024-06-30
635.7 K
Privium Fund Management B.v.2024-09-30
509.1 K
Cubist Systematic Strategies, Llc2024-09-30
383.5 K
Northern Trust Corp2024-09-30
319.7 K
Xtx Topco Ltd2024-09-30
317.3 K
Venbio Partners Llc2024-09-30
9.7 M
Fmr Inc2024-09-30
5.9 M

Alx Fundamentals

About Alx Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Alx Oncology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alx Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alx Oncology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alx Stock

  0.76ME 23Andme HoldingPairCorr
  0.86VALN Valneva SE ADRPairCorr
  0.73JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Alx Stock

  0.72KZR Kezar Life SciencesPairCorr
  0.57MLYS Mineralys Therapeutics,PairCorr
  0.35MDGL Madrigal PharmaceuticalsPairCorr
  0.32NXGLW NexGel WarrantPairCorr
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out Alx Oncology Piotroski F Score and Alx Oncology Altman Z Score analysis.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.10)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.49)
Return On Equity
(0.99)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.